FDA warning letter · #716822
DirectMeds: What the FDA Letter Means for What You Pay
Legal name: directmeds.com, Inc.
Primary source
Read the original letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025
What FDA cited
Read the full letter →Quoted verbatim from the FDA letter dated
“This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://directmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
“"If you've looked into brand-name versions of semaglutide, you know the cost can be steep – especially without insurance. That's where buying compounded semaglutide online can make a big difference. Compounded medications are created by licensed compounding pharmacies using the same active ingredients."”
“"Compounded semaglutide contains the same active ingredient as branded semaglutide."”
“"Don't give up hope if brand-name Mounjaro is out of reach due to cost. You may be able to get compounded tirzepatide online, which is an effective and budget-friendly alternative. Compounded formulations use the same active ingredient as the brand-name drug, customized by licensed compounding pharmacies to meet your needs."”
“Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”
Is DirectMeds still operating?
directmeds.com returned a live storefront when we checked in August 2026, still marketing GLP-1 medications under the same DirectMeds branding named in the FDA letter.
What this means for what you pay
This is the letter in our roster closest to Doseworth's own beat: DirectMeds marketed its compounded price as a budget alternative to the branded drug on the strength of "same active ingredient" language. FDA's objection is to that comparison, not to the price itself — it says nothing about whether DirectMeds' pricing is accurate or fair, only that the same-as-the-brand pitch overstated what FDA has evaluated.
Has DirectMeds responded?
As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence DirectMeds failed to respond.
Sources
Other letters in this index
View the full index →Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.